Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
Stoke Therapeutics Announces Proposed Public Offering
Investors are stocking up on Stoke, sending the biotech’s shares flying 90% pre-market on the back of positive phase 1/2a data for a seizure medicine.
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Stoke Announces Data of the STK-001 for the Treatment of Dravet Syndrome
Stoke Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Highlights Strategic Priorities and Anticipated Milestones for 2024
Stoke Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference